Gene therapy for heart failure

Journal of Cardiology

Volumn 66, Issue 3, 2015, Pages 195-200

  Greenberg, Barry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Ca2+ATPase (SERCA2a); Gene transfer therapy; Heart failure; Sarco(endo)plasmic reticulum

Indexed keywords

ADENOSINE TRIPHOSPHATASE; LENTIVIRUS VECTOR; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADENO ASSOCIATED VIRUS; FOLLOW UP; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE; HUMAN; REVIEW; UPREGULATION; VIRAL GENE THERAPY; GENE VECTOR; GENETICS; PROCEDURES;

GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84939262987     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.02.006     Document Type: Review

References (38)

1. Roger V.L. Epidemiology of heart failure. Circ Res 2013, 113:646-659.
2. Guo Y., Lip G.Y., Banerjee A. Heart failure in East Asia. Curr Cardiol Rev 2013, 9:112-122.
3. Kawai Y., Inoue N., Onishi K. Clinical picture and social characteristics of super-elderly patients with heart failure in Japan. Congest Heart Fail 2012, 18:327-332.
4. Matsumori A., Furukawa Y., Hasegawa K., Sato Y., Nakagawa H., Morikawa Y., Miura K., Ohno Y., Tamakoshi A., Inaba Y., Sasayama S. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. Circ J 2002, 66:323-336.
5. Goda A., Yamashita T., Suzuki S., Ohtsuka T., Uejima T., Oikawa Y., Yajima J., Koike A., Nagashima K., Kirigaya H., Sagara K., Ogasawara K., Isobe M., Sawada H., Aizawa T. Prevalence and prognosis of patients with heart failure in Tokyo: a prospective cohort of Shinken Database 2004-5. Int Heart J 2009, 50:609-625.
6. Hall M.J., Levant S., DeFrances C.J. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief 2012, 1-8.
7. Mangalmurti S.S., Paley A., Gany F., Fisher E.A., Hochman J.S. South Asians and risk of cardiovascular disease: current insights and trends. Ethn Dis 2010, 20:474-478.
8. Cheung B.M. The cardiovascular continuum in Asia - a new paradigm for the metabolic syndrome. J Cardiovasc Pharmacol 2005, 46:125-129.
9. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., Kannel W.B., Vasan R.S. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
10. Raake P.W., Tscheschner H., Reinkober J., Ritterhoff J., Katus H.A., Koch W.J., Most P. Gene therapy targets in heart failure: the path to translation. Clin Pharmacol Ther 2011, 90:542-553.
11. Pleger S.T., Brinks H., Ritterhoff J., Raake P., Koch W.J., Katus H.A., Most P. Heart failure gene therapy: the path to clinical practice. Circ Res 2013, 113:792-809.
12. Zacchigna S., Zentilin L., Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res 2014, 114:1827-1846.
13. Higuchi K., Medin J.A. Lentiviral vectors for gene therapy of heart disease. J Cardiol 2007, 49:1-11.
14. Pulicherla N., Shen S., Yadav S., Debbink K., Govindasamy L., Agbandje-McKenna M., Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011, 19:1070-1078.
15. Ishikawa K., Tilemann L., Fish K., Hajjar R.J. Gene delivery methods in cardiac gene therapy. J Gene Med 2011, 13:566-572.
16. Ishikawa K., Aguero J., Naim C., Fish K., Hajjar R.J. Percutaneous approaches for efficient cardiac gene delivery. J Cardiovasc Transl Res 2013, 6:649-659.
17. Tilemann L., Ishikawa K., Weber T., Hajjar R.J. Gene therapy for heart failure. Circ Res 2012, 110:777-793.
18. Gwathmey J.K., Copelas L., MacKinnon R., Schoen F.J., Feldman M.D., Grossman W., Morgan J.P. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987, 61:70-76.
19. Zima A.V., Bovo E., Mazurek S.R., Rochira J.A., Li W., Terentyev D. Ca handling during excitation-contraction coupling in heart failure. Pflugers Arch 2014, 466:1129-1137.
20. Braunwald E. The war against heart failure: the Lancet lecture. Lancet 2014, [Epub ahead of print].
21. Zarain-Herzberg A., Afzal N., Elimban V., Dhalla N.S. Decreased expression of cardiac sarcoplasmic reticulum Ca(2+)-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem 1996, 163/164:285-290.
22. Qi M., Shannon T.R., Euler D.E., Bers D.M., Samarel A.M. Downregulation of sarcoplasmic reticulum Ca(2+)-ATPase during progression of left ventricular hypertrophy. Am J Physiol 1997, 272:H2416-H2424.
23. Cadre B.M., Qi M., Eble D.M., Shannon T.R., Bers D.M., Samarel A.M. Cyclic stretch down-regulates calcium transporter gene expression in neonatal rat ventricular myocytes. J Mol Cell Cardiol 1998, 30:2247-2259.
24. Hasenfuss G., Reinecke H., Studer R., Meyer M., Pieske B., Holtz J., Holubarsch C., Posival H., Just H., Drexler H. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 1994, 75:434-442.
25. Meyer M., Schillinger W., Pieske B., Holubarsch C., Heilmann C., Posival H., Kuwajima G., Mikoshiba K., Just H., Hasenfuss G., Flesch M., Schwinger R.H., Schnabel P., Schiffer F., van Gelder I., et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995, 92:778-784.
26. 2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med (Berl) 1996, 74:321-332.
27. 2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995, 92:3220-3228.
28. Chaudhri B.B., Del M.F., Harding S.E., Hajjar R.J. Gene transfer in cardiac myocytes. Surg Clin North Am 2004, 84:141-159. ix-x.
29. Bouyon S., Roussel V., Fromes Y. SERCA2a gene therapy can improve symptomatic heart failure in delta-sarcoglycan-deficient animals. Hum Gene Ther 2014, 25:694-704.
30. Xin W., Li X., Lu X., Niu K., Cai J. Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced by chronic myocardial ischaemia. Acta Cardiol 2011, 66:57-64.
31. Byrne M.J., Power J.M., Preovolos A., Mariani J.A., Hajjar R.J., Kaye D.M. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008, 15:1550-1557.
32. Kawase Y., Ly H.Q., Prunier F., Lebeche D., Shi Y., Jin H., Hadri L., Yoneyama R., Hoshino K., Takewa Y., Sakata S., Peluso R., Zsebo K., Gwathmey J.K., Tardif J.C., et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008, 51:1112-1119.
33. Del M.F., Williams E., Lebeche D., Schmidt U., Rosenzweig A., Gwathmey J.K., Lewandowski E.D., Hajjar R.J. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001, 104:1424-1429.
34. Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., Ly H., Kawase Y., Wagner K., Borow K., Jaski B., London B., Greenberg B., Pauly D.F., Patten R., et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008, 14:355-367.
35. 2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313.
36. Zsebo K., Yaroshinsky A., Rudy J.J., Wagner K., Greenberg B., Jessup M., Hajjar R.J. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014, 114:101-108.
37. Karakikes I., Hadri L., Rapti K., Ladage D., Ishikawa K., Tilemann L., Yi G.H., Morel C., Gwathmey J.K., Zsebo K., Weber T., Kawase Y., Hajjar R.J. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther 2012, 20:565-571.
38. Greenberg B., Yaroshinsky A., Zsebo K.M., Butler J., Felker G.M., Voors A.A., Rudy J.J., Wagner K., Hajjar R.J. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2014, 2:84-92.